Hemin

Samip Mutha joins Robosoft Technologies as Head of UK operations from RPG Group

Retrieved on: 
Monday, February 20, 2023
Entertainment, London and Partners, UK, Europe and Africa Malankara Orthodox Diocese, Savitribai Phule Pune University, IBM, Global leadership, HCL, Country, E-commerce, RPG Group, CXO, Kerala University of Digital Sciences, Innovation and Technology, Digital economy, Government, The X Factor Digital Experience, ISB, Entrepreneurship, Hemin, ECS, Mechanical, IEEE Corporate Innovation Recognition, Financial services, Partner, Innovation, Customer experience, School, Zensar Technologies, Digital, Management, Cryptocurrency

LONDON, Feb. 20, 2023 /PRNewswire/ -- Robosoft Technologies has recently appointed Samip Mutha as Executive Vice President & Country Head – UK.

Key Points: 
  • LONDON, Feb. 20, 2023 /PRNewswire/ -- Robosoft Technologies has recently appointed Samip Mutha as Executive Vice President & Country Head – UK.
  • Welcoming Samip on board, Ravi Teja Bommireddipalli, Managing Director & CEO of Robosoft Technologies, said, "We are thrilled to have such an experienced and accomplished leader drive our ambitious growth plans in UK & Europe.
  • "There is a great opportunity to expand the tremendous equity of Robosoft Technologies in the UK & Europe markets.
  • Robosoft Technologies worked with London & Partners – 'the business growth and destination agency for London', in setting up the UK & Europe operations.

Alnylam Announces Approval of GIVLAARI™ (givosiran) by the U.S. Food and Drug Administration (FDA)

Retrieved on: 
Wednesday, November 20, 2019
Science, Biotechnology, Research, Pharmaceutical, Health, FDA, Genetics, Other Health, Alnylam Pharmaceuticals, Therapeutic gene modulation, RTT, Biotechnology, Porphyria, Hemin, Life sciences, Biology

GIVLAARI was shown to significantly reduce the rate of porphyria attacks that required hospitalizations, urgent healthcare visits or IV hemin administration at home.

Key Points: 
  • GIVLAARI was shown to significantly reduce the rate of porphyria attacks that required hospitalizations, urgent healthcare visits or IV hemin administration at home.
  • As previously reported, one patient in the GIVLAARI clinical development program experienced an anaphylactic reaction which resolved with medical management.
  • Alnylam is committed to helping people access the medicines they are prescribed and will be offering comprehensive support services for people prescribed GIVLAARI through Alnylam Assist.
  • In addition, Mount Sinai faculty are named Co-Inventors with Alnylam on a patent related to the development of givosiran, the study drug.